tiprankstipranks
NRX Pharmaceuticals Eyes $30M Refinancing and Funding Deal
Company Announcements

NRX Pharmaceuticals Eyes $30M Refinancing and Funding Deal

Don't Miss our Black Friday Offers:

NRX Pharmaceuticals (NRXP) just unveiled an update.

A company has announced through a press release that it has agreed on a non-binding term sheet, which could provide up to $7.5 million to refinance existing toxic debt, with a potential for an extra $22.5 million in additional funding. The total accessible capital could reach $30 million, but this is contingent upon successful due diligence and the finalization of binding agreements.

For a thorough assessment of NRXP stock, go to TipRanks’ Stock Analysis page.

Related Articles
TipRanks Auto-Generated NewsdeskNRX Pharmaceuticals Strengthens Leadership with New CFO Appointment
TipRanks Auto-Generated NewsdeskNRx Pharmaceuticals Reports Progress in Drug Development
TheFlyNRx Pharmaceuticals names Michael Abrams as CFO
Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App